TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04950049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diluted dexamethasone 10ml
Description: receive 10ml dexamethasone (1mg/ml) diluted with 5% glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diluted dexamethasone 20ml
Description: receive 20ml dexamethasone (0.5mg/ml) diluted with 5% glucose
Study: NCT06453161

Intervention type: OTHER
Intervention: Post-operative acute kidney injury
Description: Serum creatinine increase by 0.3 mg/dl within 48 h OR Serum creatinine ≥ 1.5-1.9 times baseline within 7 days~Baseline creatinine is defined as the last pre-operative value available in the medical file
Study: NCT06455319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG)
Description: ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verapamil extended release capsule
Description: Open label administration at 120, 240 or 360 mg daily based on weight and ECG findings

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.V. Saline
Study: NCT05114902

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: A sample obtained from the nasopharynx for detection of live pneumococci and pneumococcal respiratory carriage

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: A sample obtained from the nasopharynx for detection of live pneumococci and pneumococcal respiratory carriage
Study: NCT05117554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casdatifan
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casdatifan
Description: Capsule
Study: NCT05102656

Intervention type: OTHER
Intervention: Best Practice
Description: Physician conversations occur in-person

Intervention type: PROCEDURE
Intervention: Discussion
Description: Physician conversations occur via video call

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05532618

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block
Description: Before anterior cruciate ligament surgery an adductor canal block will be placed using ultrasound.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Adductor canal block
Description: Before anterior cruciate ligament surgery an adductor canal block will be placed using ultrasound.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Levobupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 ml of sodium chloride 0.9%
Study: NCT06045871

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Corticotomy followed by compression osteogenesis
Description: Surgical corticotomy supra apical in anterior maxilla then application of the compression osteogenesis concept via traction on miniscrews implanted above the corticotomy line
Study: NCT06445361

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FibroScan
Description: Performance of a FibroScan measurement to determine steatosis and fibrosis.
Study: NCT04658771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-HIFU treatment
Description: MR-HIFU is an innovative technology that allows for non-invasive thermal ablation of tissues and tumors by integrating an external high intensity focused ultrasound (HIFU) transducer with a conventional MRI scanner.~The focused ultrasound transducer is placed outside of the body and generates and focuses acoustic energy to heat tumors or other pre-defined focal regions of tissues inside the body. Because the acoustic energy is precisely focused over tiny areas of tissue, potential thermal injury to surrounding tissues is minimal. Cell death inside the selected treatment area occurs via coagulative necrosis while avoiding injury to intervening and adjacent tissues.
Study: NCT05117554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casdatifan
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casdatifan
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casdatifan
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casdatifan
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casdatifan
Description: Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup solution
Study: NCT03896711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEMORI Corps program
Description: Activity-based companion care program. Delivered by trained senior volunteers, supported by a clinical team, over a 12-week intervention period (8 hours per week, 2 or 3 days per week) for each person with dementia/family caregiver dyad. Primary roles of the volunteers are to provide in-home supervision, peer-to-peer companionship, and a evidence-based individualized activity program that focuses on meaningful, engaging and enjoyable activities that match PWD abilities and interests.

Intervention type: OTHER
Group type: OTHER
Intervention: Augmented Waitlist Control
Description: Persons with dementia/caregivers will continue any services and supports being used, will receive a free copy of A Caregiver's Guide to Dementia: Using Activities and Other Strategies to Prevent, Reduce and Manage Behavioral Symptom103), written educational materials on management of CG stress/well-being, and bi-weekly check-in calls to answer any questions about the materials. Volunteers randomized to waitlist control will continue with usual activities (volunteer or other), and will receive additional written educational materials on cognitive health (NIA) and exercise and Physical Activity (Go4Life), referrals to the Baltimore City Commission on Aging and Retirement Education for volunteering opportunities, and bi-monthly check-in calls to answer questions and maintain engagement. Waitlist dyads will be followed at specified intervals by the research team and then offered an opportunity for participation in the intervention arm.
Study: NCT06035861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XBD173
Description: Participants will be treated with XBD173 90mg twice daily for 6 weeks
Study: NCT04887935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: -The 10 mg dose is reflective of current clinical practice for diabetes and heart failure
Study: NCT05995431

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling and root planing
Description: All the participants will undergo scaling and root planing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subgingival instrumentation
Description: All the participants will undergo subgingival instrumentation
Study: NCT05281003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Biological: Pembrolizumab 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Drug: Paclitaxel 150 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Drug: Cisplatin 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
Study: NCT06528535

Intervention type: OTHER
Intervention: Health promotion intervention
Description: Health promotion activities on nutrition with distribution of baskets of fresh fruits and vegetables
Study: NCT05245721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: Caudal nalbuphine injection in pediatrics undergoing infra-umbilical surgeries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Caudal bupivacaine in pediatrics undergoing infra-umbilical surgeries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Caudal bupivacaine in pediatrics undergoing infra-umbilical surgeries
Study: NCT05880082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin: 70mg d1 Q3W
Study: NCT05913206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambiguity
Description: The intervention is a novel communication approach to communicate ambiguity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambiguity
Description: The intervention is a novel communication approach to communicate ambiguity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
Study: NCT05744791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Play planned movement program
Description: Teachers will implement an addition two physical activity opportunities that incorporate active play each day for a potential dose of 20-30 minutes per day and 100-150 minutes per week.
Study: NCT05424211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music Therapy Mobile Application
Description: The authorities determined by taking consultancy from TÜMATA (Turkish Music Research and Promotion Group) will be uploaded to the mobile application developed by the software specialist. The maqams (Rast, Nihavent and Neva) to be used in the application will be played to the patients 3 times in half an hour at different times of the day via the mobile application. Rast tonality will be played in the morning, nihavent tune will be played at noon and neva tune will be played in the afternoon.
Study: NCT04780217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through IV drip or pumping.
Study: NCT04557527

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pars plana vitrectomy, laser or cryo retinopexy and intraocular gas tamponade
Description: Conventional pars plana vitrectomy procedure is used to treat rhegmatogenous retinal detachment- laser or cryo retinopexy intraocular gas tamponade (SF6, C2F6 or C3F8) are chosen according to the number and size of the causative retinal break(s) and surgeons clinical judgement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suprachoroidal viscobuckle with 2.3% Sodium hyaluronate (Healon 5 Ophthalmic viscoelastic device)
Description: After drainage of subretinal fluid, approximately 0.5 ml of Healon 5 is injected in to the suprachoroidal space underlying the retinal break. Laser retinopexy is applied around the break .
Study: NCT04809792

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT on the MR-Linac
Description: Radiotherapy is performed on the 1.5 T MR Linac
Study: NCT05527730

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of PRO-FIT or SELF-FIT fitting
Description: add

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Comparison of PRO-FIT or SELF-FIT fitting
Description: add
Study: NCT06489093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSF
Description: Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of NSF using a microapplicator on the carious lesion for 1 minute. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SDF+KI
Description: Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of 38% silver diamine fluoride (Riva star 38%, SDI) using a microapplicator on the carious lesion. Immediately afterwards, potassium iodide is applied as a reducing agent. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Subjects will receive oral hygiene instructioins to apply fluoridated toothpaste to a toothbrush and brush teeth thoroughly for at least 2 minutes, then expectorate and rinse.
Study: NCT05849532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: 12-weeks of training sessions that include initial screening and clinical assessment (Week 1-2), onsite training sessions (Week 3-4), home training sessions (Week 4-8). There will also be pre (Week 1), mid (Week 7) and post-training (Week 12) assessment. Each session will consist of a 10-minute warm-up session with 5-6 stretching exercises. Warm-up will be followed by a 30 minute training session comprising of mobility, balance and walking exercises with FES. This will be followed by a cool down session for 10-minutes comprising of 5-6 muscle stretches. The participant will first watch video of the each exercise on the android tablet and then perform the exercises.
Study: NCT01433393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05232435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilate mat exercise will be performed
Description: pilate group:1- bridging 2- shoulder bridge 3- front support 4- spine stretch forward 5- spine twist plus standard treatment(stretch hamstring -stretch lower back - strength abdominal muscles - electrical heat pad)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MET
Description: Will receive MET for hamstring and erectorspinae plus standard treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group receive standard treatment
Description: electrical heat pad - stretch hamstring - stretch lower back muscles - stregth abdominal muscles
Study: NCT06059534

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplementation with placebo.
Description: Volunteers will be provided with the placebo capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with DracoBelleTM Nu.
Description: Volunteers will be provided with the DracoBelleTM Nu capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
Study: NCT05016037

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lexically based speech recast
Description: a child's spontaneous or elicited production containing phonological errors is immediately followed with a clinician model that corrects the error(s) at the word level rather than the isolated phoneme level. As an example, a speech recast of child's production of the word bake as \[be\] would be the whole lexeme bake \[bek\] rather than production drill on \[k\] in isolation.
Study: NCT05881135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: i.v. bolus administration every 12 hours for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: i.v. bolus administration every 12 hours for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: i.v. bolus administration every 12 hours for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline/Placebo
Description: i.v. administered every 12 hours as a 10 ml bolus for 5 days.
Study: NCT05158881

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy
Description: Near-infrared spectroscopy (NIRS) offers the non-invasive continuous monitoring of cerebral oxygenation and perfusion. Cerebral regional oxygen (crSO2) measured via NIRS represents a mixed tissue saturation value, thus enabling information on the balance of cerebral oxygen delivery and oxygen consumption.

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy
Description: Near-infrared spectroscopy (NIRS) offers the non-invasive continuous monitoring of cerebral oxygenation and perfusion. Cerebral regional oxygen (crSO2) measured via NIRS represents a mixed tissue saturation value, thus enabling information on the balance of cerebral oxygen delivery and oxygen consumption.
Study: NCT04912596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate inhalation aerosol 108 mcg per actuation
Description: equal to albuterol 90 mcg/puff, MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation
Description: equal to albuterol 90 mcg/puff, MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation
Description: equal to albuterol 90 mcg/puff, MDI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo
Description: MDI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo
Description: MDI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo
Description: MDI
Study: NCT06197685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Kessler Foundation modified Story Memory Technique® (KF-mSMT®)
Description: KF-mSMT is a memory retraining technique that consists of two-related skills: (1) imagery and (2) context/organization. The proposed KF-mSMT intervention includes 10 total sessions with 2 sessions per week for 5 weeks. Each session will last 45-60 minutes.
Study: NCT04912596

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol Sulfate inhalation Placebo
Description: MDI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate inhalation Placebo
Description: MDI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate inhalation Placebo
Description: MDI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate inhalation Placebo
Description: MDI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Methacholine
Description: Methacholine 100 mg/vial

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine
Description: Methacholine 100 mg/vial

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine
Description: Methacholine 100 mg/vial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methacholine
Description: Methacholine 100 mg/vial
Study: NCT06197685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Kessler Foundation modified Story Memory Technique® (KF-mSMT®)
Description: KF-mSMT is a memory retraining technique that consists of two-related skills: (1) imagery and (2) context/organization. The proposed KF-mSMT intervention includes 10 total sessions with 2 sessions per week for 5 weeks. Each session will last 45-60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET) plus Virtual Reality (IDEAL)
Description: The AET condition includes 12 weeks of supervised, progressive, moderate intensity cycle ergometry. The AET will include semi-immersive, interactive VR such the cycling speed on the bike will translate directly to perceived speed through the virtual environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching and Toning (S/T)
Description: The S/T condition will include 12 weeks of supervised S/T activities that target the head/neck. shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
Study: NCT05729477

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: miCOR System
Description: The miCOR system is a lens fragmentation device used to break up the cataract prior to IOL implantation during cataract surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: miCOR System
Description: The miCOR system is a lens fragmentation device used to break up the cataract prior to IOL implantation during cataract surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phaco Subject Cohort
Description: Phaco Subject Cohort
Study: NCT05549479

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Matching
Description: Participants will be matched with a peer based on evidence informed criteria. Partners will independently communicate and support each other around exercise for the duration of the study.
Study: NCT04100109

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polylactose
Description: Polylactose 15 g/day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Cellulose 15 g/day
Study: NCT04866862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Fruquintinib and Camrelizumab
Description: Fruquintinib 5mg d1-21+Camrelizumab 200 mg d1
Study: NCT05080881

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: phonocardiographic measurement: InnoVital Systems
Description: The instrument consists of one or more low-profile microphones in plastic housings with nitrile or silicon diaphragms. These sensors convert heart sounds into analog signals that will be acquired by the BIOPAC data acquisition system.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: phonocardiographic measurement: ThinkLabs StethOne
Description: This device senses heart sounds and may be listened to using headphones and converted to an analog signal and saved using the BIOPAC data acquisition system.
Study: NCT05549479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Matching
Description: Participants will be matched with a peer based on evidence informed criteria. Partners will independently communicate and support each other around exercise for the duration of the study.